Potent cardioprotective effect of the 4-anilinoquinazoline derivative PD153035: Involvement of mitochondrial KATP channel activation

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Cavalheiro, Renata A ^a   Marin, Rodrigo M ^a   Rocco, Silvana A ^a   Cerqueira, Fernanda M ^b   da Silva, Camille C Caldeira ^b   Rittner, Roberto ^a   Kowaltowski, Alicia J ^b   Vercesi, Anibal E ^a   Franchini, Kleber G ^a   Castilho, Roger F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CYANIDE; POTASSIUM ION; SILVER;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DRUG MECHANISM; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; POTASSIUM TRANSPORT; RAT; REPERFUSION INJURY;

ADENOSINE TRIPHOSPHATE; ANIMALS; BIOLOGICAL TRANSPORT; CALCIUM; CARDIOTONIC AGENTS; CELL RESPIRATION; CYANIDES; HEART FUNCTION TESTS; ION CHANNEL GATING; MALE; MICE; MITOCHONDRIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERMEABILITY; PHOSPHORYLATION; POTASSIUM; POTASSIUM CHANNELS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RATS; RATS, WISTAR;

RATTUS;

EID: 77956273131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010666     Document Type: Article

References (53)

1. Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M (2003) Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys 420: 222-236.
2. Facundo HT, Fornazari M, Kowaltowski AJ (2006) Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta 1762: 202-212.
3. Halestrap AP, Clarke SJ, Khaliulin I (2007) The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 1767:1007-1031.
4. Baines CP (2009) The mitochondrial permeability transition pore and ischemiareperfusion injury. Basic Res Cardiol 104: 181-188.
5. Crompton M (1999) The mitochondrial permeability transition pore and its role in cell death. Biochem J 341: 233-249.
6. Kowaltowski AJ, Castilho RF, Vercesi AE (2001) Mitochondrial permeability transition and oxidative stress. FEBS Lett 495: 12-15.
7. Duchen MR, McGuinness O, Brown LA, Crompton M (1993) On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 27: 1790-1794.
8. Facundo HT, de Paula JG, Kowaltowski AJ (2005) Mitochondrial ATP-sensitive K + channels prevent oxidative stress, permeability transition and cell death. J Bioenerg Biomembr 37: 75-82.
9. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, et al. (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481.
10. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136.
11. Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT (1998) Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem 273: 18092-18098.
12. + channel in cardiac function and cardioprotection. Biochim Biophys Acta 1606: 1-21.
13. Gross GJ, Peart JN (2003) KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285: H921-H930.
14. + channel activity. Free Radic Biol Med 40: 469-479.
15. Auchampach JA, Grover GJ, Gross GJ (1992) Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate. Cardiovasc Res 26: 1054-1062.
16. Jaburek M, Yarov-Yarovoy V, Paucek P, Garlid KD (1998) State-dependent inhibition of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate. J Biol Chem 273: 13578-13582.
17. Mubagwa K, Flameng W (2001) Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 52: 25-39.
18. Cohen MV, Baines CP, Downey JM (2000) Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol 62: 79-109.
19. Wojtovich AP, Brookes PS (2009) The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels. Basic Res Cardiol 104: 121-129.
20. Costa AD, Garlid KD, West IC, Lincoln TM, Downey JM, et al. (2005) Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria. Circ Res 97: 329-336.
21. Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70: 240-253.
22. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465.
23. Yamazaki T, Komuro I, Yazaki Y (1998) Signalling pathways for cardiac hypertrophy. Cell Signal 10: 693-698.
24. Suc I, Meilhac O, Lajoie-Mazenc I, Vandaele J, Jürgens G, et al. (1998) Activation of EGF receptor by oxidized LDL. FASEB J 12: 665-671.
25. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, et al. (2002) Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106: 909-912.
26. Nuntharatanapong N, Chen K, Sinhaseni P, Keaney JF, Jr. (2005) EGF receptor-dependent JNK activation is involved in arsenite-induced p21Cip1/Waf1 upregulation and endothelial apoptosis. Am J Physiol Heart Circ Physiol 289: H99-H107.
27. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292: C82-97.
28. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, et al. (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265: 1093-1095.
29. Rocco SA, Barbarini JE, Rittner R (2004) Syntheses of some 4-anilinoquinazoline derivatives. Synthesis 3: 429-435.
30. Domingos PP, Fonseca PM, Nadruz W, Jr., Franchini KG (2002) Load-induced focal adhesion kinase activation in the myocardium: role of stretch and contractile activity. Am J Physiol Heart Circ Physiol 282: H556-H564.
31. Claycomb WC, Lanson NA, Jr., Stallworth BS, Egeland DB, Delcarpio JB, et al. (1998) HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 95:2979-2984.
32. Seymour EM, Wu SY, Kovach MA, Romano MA, Traynor JR, et al. (2003) HL-1 myocytes exhibit PKC and KATP channel-dependent delta opioid preconditioning. J Surg Res 114: 187-194.
33. Karsten U (1980) Fluorometric estimation of dead cells in cell suspensions. Experientia 36: 263-264.
34. + channel of heart mitochondria. Am J Physiol Heart Circ Physiol 280: H649-H657.
35. + channels are redox-sensitive pathways that control reactive oxygen species production. Free Radic Biol Med 42: 1039-1048.
36. Scarpa A (1979) Measurements of cation transport with metallochromic indicators. Methods Enzymol 56: 301-338.
37. + channels. Possible mechanism of cardioprotection. Circ Res 81: 1072-1082.
38. Spector NL, Yarden Y, Smith B, Lyass L, Trusk P, et al. (2007) Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA 104:10607-10612.
39. + cycle. Biochim Biophys Acta 1606: 23-41.
40. + channel (mitoKATP) and its inward rectifier subunit (mitoKIR). J Biol Chem 279:32562-32568.
41. Szewczyk A, Skalska J, Głab M, Kulawiak B, Malińska D, et al. (2006) Mitochondrial potassium channels: from pharmacology to function. Biochim Biophys Acta 1757: 715-720.
42. + channels increases ischemic ATP levels by preventing hydrolysis. J Bioenerg Biomembr 34: 285-298.
43. + channel protects the ischemic heart. Am J Physiol Heart Circ Physiol 283:H284-H295.
44. Murata M, Akao M, O'Rourke B, Marbán E (2001) Mitochondrial ATPsensitive potassium channels attenuate matrix Ca2+ overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res 89:891-898.
45. Ishida H, Hirota Y, Genka C, Nakazawa H, Nakaya H, et al. (2001) Opening of mitochondrial KATP channels attenuates the ouabain-induced calcium overload in mitochondria. Circ Res 89: 856-858.
46. Doyle ME, Egan JM (2003) Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev 55: 105-131.
47. Prada PO, Ropelle ER, Mourão RH, de Souza CT, Pauli JR, et al. (2009) An EGFR Tyrosine-Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet-Fed Mice. Diabetes 58: 2910-2919.
48. Fry DW (1999) Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 82: 207-218.
49. Ciardiello F (2000) Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60 Suppl 1: 25-32.
50. Rewcastle GW, Denny WA, Showalter HD (2000) Synthesis of 4-(phenylamino) pyrimidine derivatives as ATP-competitive protein kinase inhibitors with potential for cancer chemotherapy. Curr Org Chem 4: 679-706.
51. Arteaga CL, Baselga J (2003) Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. Clin Cancer Res 9: 1579-1589.
52. Liu N, Li M, Li X, Meng X, Yang G, et al. (2009) PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med 50: 303-308.
53. Minarini A, Budriesi R, Chiarini A, Leonardi A, Melchiorre C (1998) Search for alpha(1)-adrenoceptor subtypes selective antagonists: Design, synthesis and biological activity of cystazosin, an alpha(1D)-adrenoceptor antagonist. Bioorg Med Chem Lett 8: 1353-1358.